	US 11,714,087 B2
	Treatment of necroptosis
Rajiv Jalan, London (GB); Fausto Andreola, London (GB); Stewart MacDonald, London (GB); and Takayuki Kondo, London (GB)
Filed by Rajiv Jalan, London (GB); Fausto Andreola, London (GB); Stewart MacDonald, London (GB); and Takayuki Kondo, London (GB)
Filed on Sep. 21, 2020, as Appl. No. 17/26,592.
Application 17/026,592 is a continuation of application No. PCT/GB2019/050815, filed on Mar. 21, 2019.
Claims priority of application No. 1804515 (GB), filed on Mar. 21, 2018.
Prior Publication US 2021/0072242 A1, Mar. 11, 2021
Int. Cl. G01N 33/573 (2006.01); A61P 1/16 (2006.01); A61K 31/4178 (2006.01); A61K 45/06 (2006.01)

CPC G01N 33/573 (2013.01) [A61K 31/4178 (2013.01); A61K 45/06 (2013.01); A61P 1/16 (2018.01); G01N 2333/912 (2013.01); G01N 2800/085 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01)]

5 Claims

1. A method of treating or preventing liver failure in an individual in need thereof, said method comprising a step of administering to said individual an antagonist of RIPK1, MLKL or RIPK3, wherein the liver failure is acute-on-chronic liver failure (ACLF).